circumstances. In this regard, adenosine is involved in T cell receptor signaling (15) , heart rate (16), blood pressure (17) , renal function (18) , inflammatory responses (19, 20) and neurotransmission (21). ADA plays a critical role in controlling the concentration of adenosine, thereby affecting many areas of intercellular signaling. Thus, in the absence of ADA, the uncontrolled elevations of adenosine could unleash a variety of adenosine signaling cascades with detrimental effects on numerous areas of physiology. The other ADA substrate, 2'-deoxyadenosine, is known to be cytotoxic by interference with a number of critical metabolic pathways. High levels of 2'-deoxyadenosine may lead to the interference of transmethylation reactions (22) , reduction of deoxynucleotide synthesis (2) , or activation of the apoptotic caspase cascade (23) . We have previously shown that some tissues in mice, especially the thymus and spleen, produce high levels of 2'-deoxyadenosine (24, 25) , making them especially sensitive to metabolic consequences of 2'-deoxyadenosine-induced metabolic cytotoxicity. We have also shown that the murine fetal liver is sensitive to 2'-deoxyadenosine elevations (26). Thus, ADA deficiency may provoke a variety of consequences, either through metabolic disturbances caused by elevated 2'-deoxyadenosine, or cell signaling disturbances caused by elevated adenosine. 5 mice develop severe abnormalities including rib cage alterations, renal abnormalities, and pulmonary insufficiency (25) . The mice fail to thrive and die from respiratory insufficiency by three weeks of age (25, 27 ).
ADA-deficient mice serve as a useful model for elucidating the biochemical basis of the various phenotypic abnormalities associated with the loss of ADA function. In considering the complexity of the phenotypes associated with ADA deficiency in humans and mice, it is likely that some features may be attributed to alterations in adenosine signaling, whereas others are due to 2'-deoxyadenosine-induced metabolic disturbances. Here we report the use of ADA enzyme therapy to regulate the level of metabolic disturbances associated with ADA deficiency and show that relatively low levels of ADA enzyme therapy correct the pulmonary abnormalities. Much higher doses of enzyme therapy are required to alleviate the immunodeficiency, a finding relevant to the use of enzyme therapy to treat ADA deficiency in humans. Available evidence suggests that the pulmonary insufficiency in ADA-deficient mice results from abnormalities in adenosine signaling (27) , whereas the immunodeficiency stems largely from 2'-deoxyadenosineinduced metabolic cytotoxicity.
Thus, ADA enzyme therapy serves as a convenient experimental strategy to regulate the metabolic consequences of ADA deficiency and differentially correct abnormalities associated with ADA deficiency.
EXPERIMENTAL PROCEDURES
Transgenic mice-Mice heterozygous for the null Ada allele (m1/+) and carrying a placentaspecific ADA minigene necessary for prenatal rescue (Tg) were intercrossed (25) . Genotypes were determined by Southern blot analysis of genomic DNA obtained from tails at weaning (25) .
Wild type (+/+) and heterozygous (m1/+) mice with or without the ADA minigene (Tg) were designated as "ADA+ controls", whereas homozygous mutant mice carrying the ADA minigene (Tg-m1/m1) were designated ADA-deficient (25) . All mice were housed in cages equipped with microisolator lids and maintained under strict containment protocols.
PEG-ADA enzyme therapy-Polyethylene glycol-modified-ADA (PEG-ADA, Adagen), was kindly provided by Enzon Inc. (Piscataway, NJ). A "low-" and "high-dose" protocol was utilized. For the "low-dose" protocol, mice were injected intramuscularly with dosages of PEG-ADA designed to deliver 100 to 500 Units (1 Unit is defined as the amount of enzyme necessary to convert 1 µmole adenosine to inosine per min at 25°C) of PEG-ADA per kg body weight.
Injections were started on postnatal day three and were given every seven days for six weeks.
For the 'high-dose" protocol, mice were injected intraperitaneally with dosages of PEG-ADA designed to deliver 1000-5000 Units of PEG-ADA per kg body weight. Injections were started on postnatal day 10 and were given every three to four days.
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PBS and sonicated in three volumes of homogenizing buffer. Samples were then centrifuged at 14,000 x g at 4°C and protein concentration determined in the supernatants (Bio-Rad). Samples were run on thin agarose gels (Innovative Chemistry) in the cold, and were then overlaid with enzyme substrate and colorimetric detection cocktail (24) . For determination of ADA trough values, heparinized blood samples were collected from the tail vein of mice just prior to the next injection of PEG-ADA, and plasma isolated by low-speed centrifugation. ADA specific activity in plasma was determined using established protocols (28).
Histological analysis-Animals were sacrificed and the lungs infused with 0.5 ml of fixative (4% paraformaldehyde in PBS) prior to fixation overnight at 4ºC. Fixed lung tissues were rinsed in PBS, dehydrated, and embedded in paraffin according to standard techniques. Sections (5 µm)
were stained with hematoxylin and eosin (H&E) using a Rapid Chrome staining kit (Shandon Lipshaw). Thymuses and spleens were excised from control and ADA-deficient age-matched littermates or mice treated with PEG-ADA and processed for flow cytometry (24) . Two-color flow cytometry analysis was conducted on 1 X 10 6 viable leukocytes, and data were obtained on two-color dot plot profiles.
Flow Cytometry of Leukocyte Populations-

Analysis of adenine nucleosides and nucleotides and determination of AdoHcy hydrolase
enzymatic activity-Tissues were removed from mice and quickly frozen in liquid nitrogen.
Nucleosides and nucleotides were extracted and analyzed by HPLC according to established procedures (24, 29) . AdoHcy hydrolase enzymatic activity was determined in freshly prepared tissue extracts according to established procedures (24, 30) .
RESULTS
Stability and distribution of PEG-ADA in mice-
Before attempting to use PEG-ADA to treat ADA-deficient mice, it was necessary to conduct experiments to determine adequate PEG-ADA treatment protocols. ADA+ control mice were treated with PEG-ADA in order to monitor the consistency of drug delivery. Mice were given an intramuscular injection of PEG-ADA (2.5 to 10 µl, depending on age) once weekly for six weeks. This dose was designed to deliver between 100 and 500 Units of PEG-ADA per kg body weight. PEG-ADA levels were estimated semiquantitatively in whole blood two days following the last injection and were found to be similar in all samples (Fig. 1A) , suggesting that the treatment protocol was capable of consistently delivering enzyme to the circulation of mice. To determine the stability of PEG-ADA in the circulation, ADA+ control mice were treated with PEG-ADA as described above, and blood PEG-ADA levels were estimated at various time points following the last treatment (Fig. 1B) . At two days following the last injection, PEG-ADA levels were approximately three times greater than endogenous ADA. By four days following the last injection, blood levels had dropped, and were equivalent to endogenous ADA levels. At eight days post-PEG-ADA, only trace amounts were seen, and by 16 days post-treatment PEG-ADA was not detectable. From these results it was estimated that the half-life of PEG-ADA in the murine circulatory system was three to four days. Trough values of PEG-ADA activity achieved with this protocol are shown in Table 1 . This regimen was referred to as a "low-dose" treatment protocol, in comparison with the higher dose regimen used in later studies (see below).
PEG-ADA enzyme therapy rescues ADA-deficient mice-ADA-deficient mice die by three weeks of age in association with respiratory distress, lymphopenia and severe metabolic disturbances (25) . To determine if PEG-ADA enzyme therapy could rescue ADA-deficient mice, three-dayold pups were treated intramusculary with PEG-ADA according to the "low-dose" regimen. At three weeks of age, blood was collected and analyzed for endogenous ADA or PEG-ADA ( Fig PEG-ADA is found only in the circulatory system of ADA-deficient mice-PEG-ADA does not enter erythrocytes or blood lymphocytes of human ADA-deficient patients, however, the distribution of PEG-ADA in other tissues is not known (2,28). ADA-deficient mice provided the opportunity to examine the levels of PEG-ADA present in various non-hematopoietic tissues. Fig. 2B is the analysis of PEG-ADA activity in extracts from various tissues taken from an ADA-deficient animal two days following its last PEG-ADA injection ("low dose" regimen). Whereas PEG-ADA was detectable in the blood of this animal, it was not detected in any of the tissues examined, including the thymus, spleen, liver, kidney and lung. These data suggested that most if not all of the PEG-ADA in ADA-deficient mice was found in the circulatory system, as has been assumed to be the case in humans (2,28).
Shown in
"Low-dose" PEG-ADA treatments prevent lung inflammation and damage-ADA-deficient mice succumb to severe respiratory distress by three weeks of age (25, 27) . Lungs of these animals show defects in alveogenesis and severe lung inflammation and damage is present ( Fig. 3B ) (27).
The ability of the "low dose" PEG-ADA regimen to rescue ADA-deficient mice from lethality ( Fig. 2A) was associated with significant reduction in the severe lung inflammation and damage seen in untreated ADA-deficient mice (Fig. 3 ). These findings suggested that "low-dose" PEG-ADA provided adequate metabolic protection to prevent the pulmonary phenotype and allowed for the survival of these animals.
High doses of PEG-ADA are required to establish ADA trough values in ADA-deficient mice similar to those seen in ADA-deficient humans-
The initial treatment for seriously ill, newly diagnosed human infants with ADA-deficient SCID, is a twice weekly injection of 30 Units/kg PEG-ADA (31, 32) . This treatment protocol typically leads to trough plasma ADA activity levels that range from approximately 50-120 µmol/hr/ml (2). Based on body weight, the "low-dose" treatment protocol used in ADA-deficient mice was considerably higher than this initial dosage used in ADA-deficient humans. However, the mean trough plasma ADA activity in mice treated with this regimen was considerably lower than the trough levels observed in ADA-deficient humans ( Table 1 , (2)). Therefore, we also treated mice with 10-fold greater amounts of PEG-ADA. This "high-dose" protocol was sufficient to maintain trough plasma PEG-ADA activity at levels equivalent to that observed with a 60 Unit/kg/week regimen in ADA-deficient humans (Table 1 , (2)). These data demonstrated that much higher doses of PEG-ADA, on a per kg body weight basis, are required in the mouse to establish plasma PEG-ADA levels that are therapeutically effective in humans.
High doses of PEG-ADA overcome the block in thymocyte development seen in ADA-deficient
mice-ADA deficiency in humans (2) and mice (25) is associated with pronounced lymphopenia.
Treatment of ADA-deficient humans with PEG-ADA results in varying degrees of restoration of mature lymphoid cells (2, 31) . To begin to assess the impact of PEG-ADA enzyme therapy on lymphoid development in ADA-deficient mice, total lymphoid counts were examined in the thymuses of ADA+ control and ADA-deficient mice given either a "low-" or "high-dose" of PEG-ADA ( Fig. 4A and B) . Lymphoid counts in ADA-deficient thymuses were greatly reduced on postnatal day 17 ( Fig. 4A ). Low doses of PEG-ADA did not have a significant impact on the lymphopenia seen in the thymus (Fig. 4B) , however, the "high-dose" treatment allowed for an improvement in thymocyte counts to near control values (Fig. 4B ).
Immature thymocytes are organized into two major groups based on the cell surface expression of CD4 and CD8 (33) . The most immature thymocytes express neither CD4 or CD8
and are termed double negative (DN), while more mature thymocytes express both CD4 and CD8 and are termed double positive (DP). Flow cytometry using antibodies to specific markers of thymocyte differentiation were used to determine the effect of ADA enzyme therapy on thymocyte differentiation. The percentage of DP cells was diminished from 80% in ADA+ control thymuses to 20% in ADA-deficient thymuses on postnatal day 17 (Fig. 4C ). In addition,
there was an increase in DN cells in ADA-deficient thymuses, verifying a potential block in thymocyte differentiation before the DP stage. The distribution of DP and DN cells in ADAdeficient thymuses improved slightly following "low-dose" PEG-ADA treatment, while a "highdose" treatment improved the distribution of cells in ADA-deficient thymuses to near control values (Fig. 4D ). These data suggested that high doses of PEG-ADA are needed to see an improvement in thymocyte differentiation in ADA-deficient mice. made assessment of tissue substrate elevations possible, and it has been shown that both adenosine and 2'-deoxyadenosine are highly elevated in the circulation and in tissues of ADAdeficient mice (25, 35) . To determine what effect PEG-ADA enzyme therapy has on ADA substrates in tissues, adenine nucleosides were extracted from tissues of ADA-deficient mice treated with PEG-ADA, and were quantitated by reversed-phase HPLC (Fig. 6 ). Treatment of ADA-deficient mice with a "low-dose" regimen of PEG-ADA prevented elevations of adenosine and 2'-deoxyadenosine in the serum and lung, but not in the thymus and spleen (Fig.   6 ). In contrast, high doses of PEG-ADA were able to markedly improve the metabolic disturbances found in the serum and lung as well as the thymus and spleen (Fig. 6 ). These results demonstrated that PEG-ADA provided varying degrees of metabolic protection in the whole animal. (25, 35) . In ADA-deficient mice treated with a "lowdose" regimen of PEG-ADA, a substantial decrease in AdoHcy hydrolase activity was still noted in the thymus and spleen, and to a lesser extent in RBCs and the lung (Fig. 7A) . A "high-dose" regimen restored AdoHcy hydrolase activity in RBCs and lung and provided partial improvement in the thymus and spleen (Fig. 7A) . The levels of dATP that accumulate in RBCs of ADA-deficient mice are seven-to eight-fold higher than those measured in the thymus (25, 35) . In contrast, the levels of dATP that accumulated in the RBCs of ADA-deficient mice treated with a "low-dose" regimen of PEG-ADA were similar to those measured in other tissues from the same animals (Fig. 7B) . Elevations in dATP were noted in all tissues following a "lowdose" regimen, with the greatest relative accumulation occurring in the thymus (Fig. 7B ). This suggested that a "low-dose" of PEG-ADA was capable of preventing much of the accumulation of dATP in erythrocytes and lungs, but not dATP accumulation in other tissues. Treatment of ADA-deficient mice with a "high-dose" of PEG-ADA completely prevented the accumulation of dATP in both erythrocytes and tissues (Fig. 7B) . Improvements in these metabolic endpoints correlated with the degree of immune reconstitution, adding support to the hypothesis that metabolic abnormalities are mechanistically involved in the immune phenotypes associated with ADA deficiency.
Improvement of peripheral T, B and
AdoHcy hydrolase enzyme activity and elevations in dATP vary in tissues of
DISCUSSION
ADA deficiency in humans is most often associated with a severe combined immunodeficiency (2,6). However, additional non-lymphoid abnormalities have been noted, including bone, kidney and adrenal abnormalities (9), liver damage (8) and problems associated with the nervous system (10) . Pulmonary insufficiency in ADA-deficient patients is similar to pulmonary insufficiency seen in patients with other forms of SCID. It is not present at birth, and is most commonly found in association with known pathogens. The lung injury in ADA-deficient mice is present early in life and is not associated with infection (27). In the current study, PEG-ADA enzyme therapy was used to study the impact of tissue metabolic disturbances on the pulmonary and immune phenotypes seen in ADA-deficient mice (25, 27) . ADA-deficient mice were initially given a "low-dose" of PEG-ADA that resulted in circulating enzyme activities below plasma PEG-ADA levels achieved in patients with ADA-deficient SCID (2, 31, 32) . Nonetheless, this "low-dose" of PEG-ADA was capable of rescuing ADA-deficient mice from lethality due to pulmonary injury.
This "low-dose" treatment corrected systemic and lung accumulations of adenosine and 2'-deoxyadenosine, but did not prevent elevations of adenosine and 2'-deoxyadenosine in the thymus and spleen. Consequently, defects in lymphoid development persisted. A PEG-ADA treatment protocol designed to maintain circulating PEG-ADA activity at concentrations that are in the effective range seen in humans (31, 32) , resulted in substantial improvements in immune status as well as a major reduction in the degree of substrate elevations in the thymus and spleen.
These findings suggest that the pulmonary and immune phenotypes seen in ADA-deficient mice are separable and are mediated by the different degrees of metabolic disturbances associated with ADA deficiency.
The pulmonary phenotype seen in ADA-deficient mice is characterized by a developmental defect in alveogenesis that results in enlarged alveolar airways (27). In addition, these animals develop severe lung inflammation and damage that kills these animals by three weeks of age.
Lung damage and inflammation was associated with the elevation of adenosine and to a lesser extent, 2'-deoxyadenosine in the lungs (25) . We show that maintaining ADA-deficient mice on a "low-dose" of PEG-ADA resulted in normal lung development, and lung inflammation and elevations in ADA-deficient lungs were relatively low, the potential impact of 2'-deoxyadenosine cytotoxicity on the pulmonary phenotype cannot be ruled out at this time.
A major finding of this study was the observation that the pulmonary and immune phenotypes could be separated. This was made possible by the finding that a "low-dose" of PEG-ADA was sufficient to normalize adenosine and 2'-deoxyadenosine levels in the circulation and in the well vascularized lung, but was not sufficient to prevent substrate elevations in the thymus and spleen. Elevated thymic nucleosides are likely due to high levels of adenosine and 2'-deoxyadenosine generated in the thymus due to the large amount of apoptosis naturally occurring in this organ as a part of thymocyte development 2 (24, 25) . This idea is supported by the observation that enzyme treatments that maintained high PEG-ADA trough values were needed to achieve metabolic and phenotypic improvement in the thymus and spleen. The benefits of PEG-ADA enzyme therapy in humans have focused predominantly on the immune system; however, some studies show a rapid improvement of non-immune phenotypes following PEG-ADA treatment or red cell transfusion (8, 10) . Pulmonary insufficiency is common in ADA-deficient patients, and these insufficiencies are most often attributed to bacterial or viral pneumonia that arises from a compromised immune system. However, in many cases of interstitial pneumonia an organism cannot be isolated (2). Our observations in ADA-deficient mice suggest that it is possible that the metabolic disturbances may directly contribute to the pulmonary insufficiency occurring in ADA-deficient patients.
ADA deficiency in humans results in a severe combined immunodeficiency characterized by a depletion of T, B and NK cells (6) . All three of these cell populations were reduced in ADAdeficient mice, making them a valuable model for studying mechanisms governing the immunodeficiency seen as a result of ADA deficiency. In this model we were able to conduct 
